Clinical Trials Logo

Optic Nerve Diseases clinical trials

View clinical trials related to Optic Nerve Diseases.

Filter by:

NCT ID: NCT04381091 No longer available - Clinical trials for Leber's Hereditary Optic Neuropathy

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

US EAP LHON
Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study

NCT ID: NCT04302220 Recruiting - Eye Diseases Clinical Trials

Myopic Optic Neuropathy in Chinese High Myopia Population

Start date: June 6, 2019
Phase:
Study type: Observational [Patient Registry]

This study intends to establish a registry cohort to enroll patients with high myopia to study the natural course of myopic optic neuropathy in Chinese adult population.

NCT ID: NCT04289909 Not yet recruiting - Multiple Sclerosis Clinical Trials

Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)

RETIMUS
Start date: March 2020
Phase: N/A
Study type: Interventional

Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes occurring along the optic nerve of the brain parenchyma. Indeed, our team has been able to develop a quantitative method to measure the perivascular infiltrate in the retina of patients with various inflammatory retinal disease. It has been observed in MS patients that this perivascular infiltrate can also be detected in the retina. However, its distribution across MS phenotypes (relapsing or progressive MS, with and without optic neuritis) is still unknown.

NCT ID: NCT04125043 Completed - Retinal Disease Clinical Trials

Accuracy of the Red Reflex Test in the Pediatric Population

Start date: March 1, 2020
Phase:
Study type: Observational

This study is designed to investigate the sensitivity and specificity of the Red Reflex Test (RRT), with and without dilation, for early detection of ocular abnormalities in children and newborns. The RRT functions by shining a light from an ophthalmoscope into a participant's eye and noting the presence or absence of a red glow. Despite its use in pediatric clinics for years, this test at times fails to detect significant ocular diseases, especially located in the back of the eye, threatening visual development in this population. Therefore, the investigators aim to quantify the utility of this test as a tool for screening by comparing these findings on RRT with those of retinal photography. The investigators hypothesize that the sensitivity and specificity of the RRT will be sufficient for detecting anterior segment pathology but will be insufficient for detecting posterior segment pathology with or without dilation.

NCT ID: NCT04096612 Recruiting - Thyroid Eye Disease Clinical Trials

The Therapeutic Effect of Dysthyroid Optic Neuropathy

Start date: January 1, 2016
Phase: N/A
Study type: Interventional

Thyroid associated ophthalmopathy (TAO) is a common autoimmune disorder. The pathogenesis of TAO is unclear, and studies found that T cell, B cell and monocytes, macrophages and mast cells are located in the orbital tissue of TAO. Dysthyroid optic neuropathy (DON) is the most serious complication of TAO, which can cause blurred vision, color vision and vision function damage, and affects the quality of life. Investigation of the therapeutic effect of orbital decompression may provide some clues to make the policy at treatment of DON. We explore the therapeutic effect of orbital decompression in patients with DON in both eyes.

NCT ID: NCT03927118 Completed - Clinical trials for Diabetic Macular Edema

Effect of Dexamethasone Implant on Optic Disc

Start date: February 1, 2018
Phase:
Study type: Observational

This study evaluates the effect of dexamethasone implant which is an intraocular corticosteroid on the optic nerve fibers. Retinal nerve fiber thicknesses and optic nerve head pitting rates were measured before and 6 months after the injection.

NCT ID: NCT03851562 Recruiting - Clinical trials for Ischemic Optic Neuropathy

Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy

PG-NAION
Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

Correction of the deficit in the perfusion pressure of the microcirculation that supplies the nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected to improve visual function in patients with ischemic optic neuropathy previous non-arteritic (NOIANA).

NCT ID: NCT03760055 Enrolling by invitation - Glaucoma Clinical Trials

Assessment of Visual Function With a Portable Brain-computer Interface

Start date: February 11, 2019
Phase:
Study type: Observational

1. The purpose of this study is to evaluate the nGoggle's accuracy and repeatability in detecting visual function loss. In addition, the ability to stage glaucomatous damage and investigate the relationship between nGoggle metrics and neural damage in glaucoma will also be evaluated. 2. Longitudinal study, including 200 patients with: glaucoma, suspected of having glaucoma, nonglaucomatous optic neuropathies, AMD, retinal degenerations, other diseases involving the visual pathways, besides healthy controls. Subjects will perform standard ophthalmological exams, and the following research tests: electroencephalogram, visual evoked potentials, and questionnaires. 3. Statistical analyses will be performed by the PI using the software Stata, MATLAB, and MPLUS. Risks are low, consisting of some discomfort, fatigue, dizziness or motion sickness.

NCT ID: NCT03758118 Completed - Clinical trials for Non-arteritic Ischemic Optic Neuropathy

Citicoline in Non-Arteritic Ischemic Optic Neuropathy

Start date: February 20, 2017
Phase: N/A
Study type: Interventional

The investigators tested the hypothesis whether the treatment with Citicoline in oral solution (OS-Citicoline) would increase or stabilize visual acuity, retinal ganglion cells (RGCs) function and neural conduction along the visual pathways (neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in an human model of neurodegeneration: non-arteritic ischemic optic neuropathy (NAION).

NCT ID: NCT03715881 Recruiting - Clinical trials for Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION Treatment With Oral Prednisolone and Erythropoietin Injection

NAION
Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

This randomized double-blind clinical trial is performed on all recent (within the last 5 days) NAION patients referred to hospitals affiliated to the Shahid Beheshti University of Medical Sciences, Iran. The patients will be equally and randomly assigned into two experimental groups and a control group. The first experimental group will receive 1000 units of erythropoietin every 12 hours for three days. The second experimental group will receive 50 mg of oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued. In addition, the subjects in the second experimental group will receive 300 mg of ranitidine daily. The third group will receive placebo. Eye examination with color vision, perimetry, and peripapillary optical coherence tomography (to measure the thickness of the retinal nerve fiber layer) will be performed before the intervention, and 1, 3 and 6 months after the intervention. SITA standard visual field testing will be done using the Visual Field Analyzer Humphrey 750 Field (Carl Zeiss, USA). The thickness of the retinal nerve fiber layer will be measured by optical coherence tomography (Cirrus Zeiss Cirrus HD-OCT, Carl Zeiss, USA). The q-q plot and Kolmogorov-Smirnov tests will be performed to test normal distribution of data. Descriptive statistics including frequency, percentages, standard deviation, median and range will be used. Other statistical test including ANOVA, Kruskal-Wallis, Chi-Square, and Fischer's exact tests will be performed. All statistical analyses will be performed in SPSS (version 20) at significance level of 0.05.